Chelidonine Selectively Inhibits the Growth of Gefitinib-resistant Non-small Cell Lung Cancer Cells through the EGFR-AMPK Pathway.

•Chelidonine is a novel potential inhibitor of EGFR with L858R/T790M double mutation.•Chelidonine significantly represses G–R NSCLC cells growth in vitro and in vivo.•Chelidonine-induced apoptosis is associated with mitochondrial damage.•Targeting EGFR and inhibition of mitochondrial function to activate the AMPK signaling pathway is a potential anti-cancer therapeutic strategy for G–R NSCLC patients.